ReviewPsychopharmacology2026
Memory impairment and chronic high-dose Δ9-THC/cannabis exposure: a narrative review of molecular mechanisms underlying neurotoxic effects.
Review in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe increasing potency of cannabis and the growing prevalence of chronic, high-dose use have raised concerns about its potential neurotoxic effects on cognitive functions, particularly memory. While low-dose cannabinoids have demonstrated therapeutic benefits, the molecular basis of memory impairment under high-dose exposure remains insufficiently clarified.
objectivesThis narrative review aims to elucidate the molecular mechanisms underlying memory impairment associated with chronic, high-dose Δ9-tetrahydrocannabinol (Δ9-THC) and cannabis exposure, and to distinguish these effects from the beneficial outcomes observed at lower doses.
methodsA narrative review methodology was employed to synthesize evidence from both human studies and murine models, focusing on molecular, cellular, and neurobiological pathways involved in memory dysfunction.
resultsChronic high-dose activation of the endocannabinoid system (ECS) induces acascade of adverse molecular events, including neuroinflammation, oxidative stress, and activation of apoptotic pathways. Significant dysregulation of key neurotransmitter systems was also observed. Importantly, high-dose Δ9-THC disrupts neuroplasticity by impairing hippocampal neurogenesis, synaptogenesis, and dendritic remodeling, thereby compromising mechanisms essential for memory formation and consolidation. Adolescents and elderly individuals were identified as particularly vulnerable populations.
conclusionsChronic exposure to highdose Δ9-THC is strongly associated with memory impairment through interconnected molecular pathways. These findings provide a mechanistic framework linking cannabis exposure to cognitive deficits and highlight the need for longitudinal human studies and the development of targeted therapeutic interventions.
Indexed as
Identifiers
42062593What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.